Scientists May Know Why Astronauts Develop Health Problems In Space



[ad_1]

TipRanks

Billionaire Israel Englander Plays Money in 2 Strong Buy Shares

After the mad rush of 2020, where does the market go from here? Major progress has been made in the race for the COVID-19 vaccine, but the near-term picture remains blurry, blurred by the resurgence of the virus and the stimulus deadlock on Capitol Hill. At times like these, the greats investors can serve as inspiration, namely billionaire Israel “Izzy” Englander. Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his internship career at investment firm Oppenheimer, before purchasing a seat on the US Stock Exchange, where he would become a broker, trader and specialist. 1989, together with Ronald Shear, Englander founded the Millennium Management hedge fund. As proof of his excellent results, the guru took the $ 35 million the fund was created with and turned it into more than $ 40 billion in assets under management. With his personal net worth of $ 7.2 billion, it’s no wonder Wall Street pays attention to when Englander makes a move. With that in mind, we focused on the last 13F deposit of Millenium, which discloses the shares that the fund collected in the third. trimester. By stalling on two tickers in particular, the TipRanks database revealed that the two names are getting a consensus from “Strong Buy” analysts. Additionally, the analyst community sees enormous upside potential in store for each of them.G1 Therapeutics (GTHX) Bringing a deep understanding of cancer biology and extensive drug discovery experience to the table, G1 Therapeutics works to develop therapies that could potentially improve the lives of patients struggling with the deadly disease. Ahead of a key regulatory decision, the Street beats the table on this name. In the third quarter, Englander and Millennium acquired a new stake in GTHX. By pulling the trigger on 555,937 shares, the stake is worth $ 6,421,000. Turning to the analyst community, Needham’s Chad Messer tells his clients he has high hopes for the Feb. 15 PDUFA date for trilaciclib, his therapy designed to improve outcomes for cancer patients treated with chemotherapy. The therapy’s NDA was accepted in August for priority review based on the results of three randomized clinical studies in small cell lung cancer (SCLC), with FDA indicating it does not plan to hold a meeting of the advisory committee (AdComm). As trilaciclib is the first CDK4 / 6 inhibitor to be used to treat chemo-induced bone marrow toxicity, Messer maintains that the absence of AdComm is “significant”. Explaining this, he said: “We believe this reflects the agency’s assessment of unmet need, its comfort with the safety profile of the CDK4 / 6 class and the efficacy profile of trilaciclib. guidelines. It should also be noted that a pivotal phase 3 study evaluating the candidate in metastatic colorectal cancer (mCRC) is expected to start by the end of the year. Adding to the good news, GTHX and its partner, Boehringer Ingelheim, are joining forces. are preparing for the commercial launch of trilaciclib, with the companies covering approximately 2,500 treating oncologists and providing educational material regarding the use of trilaciclib prior to treatment and the benefits of preserving multiple lineages. under development for the treatment of estrogen receptor positive (ER +) breast cancer and the palbociclib combination was able to complete recruitment earlier than expected, reflecting “the attractiveness of an all-oral treatment regimen. during a global pandemic, ”according to Messer. With a data reading slated for the second quarter of 2021, the analyst believes that a “positive reading could prove to be a significant value driver.” In keeping with his bullish approach, Messer reiterated a buy note and price target of $ 74, indicating upside potential of 417%. (To see Messer’s track record, click here) Do the other analysts agree? They are. Only purchase ratings, 3 to be exact, have been issued in the past three months. Therefore, the message is clear: GTHX is a strong buy. Considering the average price target of $ 59, stocks could rise 312% next year. (See GTHX stock market analysis on TipRanks) Epizyme (EPZM) Also fighting the good fight against cancer, as well as against other serious diseases, Epizyme wants to find new treatments thanks to new epigenetic drugs. Even though the company faces headwinds when it comes to its recent product launch, several members of the street believe big things are in store: Millenium bought 461,258 shares in the third quarter, buying reflecting a new position for the hedge fund. As for the value of the stake, it lands at $ 5,503,000 .Writing for Wedbush, 5-star analyst David Nierengarten points out that the pandemic has limited oncologist visits and, as a result, sales of Tazverik (lymphoma treatment) company follicle) were lower than expected. . He points out that “the pandemic shifts the launch curve towards an ‘incidence model’ rather than a prevalence model, because the patient pool is limited if they delay visits to the office”, patients waiting to be done. treat until they feel Plus, although the launch is virtual and awareness among doctors is high, doctors are against prescribing a new drug without examining the patient in person. That being said, Nierengarten remains optimistic about the therapy. “Despite these headwinds, Tazverik came close to meeting our estimates, and it is gaining market share, especially seeing the initial sales in second line. We expect more significant second-line sales to start in 2021 and move them more gradually into our launch curve, ”the analyst explained. When it comes to therapy, Nierengarten says it’s too early to draw any conclusions. However, it highlights the fact that the durability of the response was relatively long and the patients were treated beyond the progress of the registration study. “Additionally, the headwind of the therapy change turns into a tailwind of the Tazverik maintenance once a patient is on treatment. This will likely contribute more significantly to 2H21 revenue and potential revenue outperformance, ”he added. Of the above, Nierengarten sides with the bulls, reiterating an outperformance note and a price target of $ 27. This goal reflects his confidence in EPZM’s ability to climb 122% higher next year. (To see Nierengarten’s track record, click here) Most other analysts echo Nierengarten’s sentiment. 3 purchases and 1 wait add up to a strong consensual purchase note. With an average price target of $ 23.25, the upside potential stands at 91%. (See EPZM Stock Market Analysis on TipRanks) For great ideas for health stocks traded at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that brings together all the information about TipRanks stocks. only those of featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

[ad_2]

Source link